FDA Accusations Send Stock Plunging 42%
An escalating conflict between uniQure and the U.S. Food and Drug Administration sent the company's stock into a tailspin after the agency publicly questioned the integrity of data for its Huntington's disease gene therapy, AMT-130. On March 2, the FDA issued a "strong" recommendation that uniQure conduct a new sham surgery-controlled study, concluding that data from its Phase I/II trial was insufficient for approval. The market reacted swiftly, with uniQure's shares plummeting 42% from $15.63 on February 27 to $9.03 two days later.
The dispute intensified when an unnamed FDA official, later identified as Dr. Vinayak Prasad, told reporters the therapy was a "failed product." UniQure fired back, calling the statements "highly irregular, unprecedented, and... incomplete or entirely incorrect." The public clash has also exposed the company to legal challenges, with law firms organizing a securities class-action lawsuit against uniQure for allegedly making misleading statements about the drug's approval prospects.
Official's Resignation Sparks 51% Stock Rebound
The narrative reversed dramatically on Friday when uniQure announced the resignation of Dr. Prasad, the FDA's Chief Medical and Scientific Officer and the primary critic of AMT-130. Investors interpreted his departure as the removal of a major obstacle to the drug's approval, triggering a massive rally in the company's stock. Shares soared 51% to $21.55 in after-hours trading, erasing the week's losses and signaling renewed confidence in the therapy's future.
This sentiment spread to the broader genetic medicine sector, with related stocks also gaining. Analysts noted the market move reflected a belief that Dr. Prasad's hard-line stance was an outlier and his exit could lead to a more conventional regulatory review process. The stock's rebound from a low of $9.03 to over $21 in a matter of days illustrates the high stakes tied to key regulatory personnel and their influence on innovative treatments.
Analysts Re-evaluate Path for $1.7B Drug
With a key regulatory opponent gone, investors and analysts are re-evaluating the path forward for AMT-130, a drug with consensus peak sales forecasts of $1.7 billion. The renewed optimism stands in stark contrast to the sentiment just days earlier, when Mizuho Securities slashed its price target on uniQure by 64% from $33 to $12, citing the risk of a lengthy and "potentially unethical" new trial. Patient advocacy groups like the Huntington’s Disease Society of America had criticized the FDA's demand for a sham surgery, arguing it would subject patients to irreversible neurodegeneration while on placebo.
While uniQure had previously reported that its Phase I/II study showed a 75% slowing of disease progression, the FDA's initial rejection highlighted the agency's stringent standards for gene therapies. Dr. Prasad's departure does not guarantee approval, but it significantly de-risks the regulatory pathway in the eyes of the market. Investors are now betting that direct and more constructive dialogue between uniQure and the FDA can resume, potentially salvaging the timeline for a therapy aimed at a fatal neurodegenerative disease with no cure.
